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Abstract 
Background 
Information on the effectiveness of beta-blockade in patients with heart failure (HF) and 
concomitant renal impairment is scarce and beta-blockers are underutilized in these patients.  
Methods and Results 
The Cockcroft-Gault formula normalized for body surface-area was used to estimate renal 
function (eGFRBSA) in 2622 patients with HF, LVEF ≤35%,  NYHA class III/IV and serum 
creatinine <300μmol/L (3.4mg/dL) in the second Cardiac Insufficiency Bisoprolol Study 
(CIBIS-II). They were divided into 4 sub-groups according to baseline eGFRBSA (< 45, 45-
60, 60-75 and ≥ 75ml/min per 1.73m2). Cox proportional-hazards models adjusted for pre-
specified confounders were used to assess the effect of bisoprolol and potential heterogeneity 
of effect across the eGFRBSA sub-groups. Older age, female-sex, diabetes and ischemic-
etiology were more common in those with reduced eGFRBSA. The hazard associated with 
bisoprolol use for all-cause mortality, the composite of all-cause mortality or heart failure-
hospitalization and heart failure-hospitalization alone was consistently <1.0 across eGFRBSA 
categories with no treatment by renal-function interaction (p=0.81, p=0.66, p=0.71 
respectively). The rate of bisoprolol discontinuation was higher in patients with eGFRBSA 
<45ml/min per1.73 m2. Nevertheless the absolute benefit of bisoprolol was greater for 
patients with chronic kidney disease compared to those without. 
Conclusions 
The beneficial effects of bisoprolol on mortality and hospitalization for worsening heart-
failure were not modified by baseline eGFRBSA. Renal impairment should not prevent the use 
of bisoprolol in patients with HF.  
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Introduction 
Renal insufficiency is a common co-morbidity amongst patients with chronic heart failure 
(HF). It is associated with a worse prognosis and complicates therapeutic management. 
Indeed renal impairment, independently of left ventricular ejection fraction (LVEF), is 
associated with neurohormonal activation and worse fatal and non-fatal outcomes in patients 
with both ischemic and non-ischemic HF1,2.  
 
In clinical trials the relative benefit of several treatments is similar in patients with and 
without renal dysfunction. As a result, these treatments provide a large absolute benefit in 
patients with heart failure and renal insufficiency. This has been shown for ACE inhibitors3, 
digoxin4 and the combination of hydralazine and  isosorbide dinitrate5. In clinical practice, 
however, HF patients with renal insufficiency are less likely to receive efficacious therapies 
than patients with normal or near normal renal function6,7. The explanation for this is 
uncertain, but may be due to a real or perceived increased risk of treatment-related adverse 
effects in patients with renal impairment. There is limited evidence about the efficacy and 
tolerability of beta-blockers in patients with heart failure and renal dysfunction, originally 
arising from observational studies7,8,9, and more convincingly from two recent post hoc 
analyses of randomized clinical trials addressing these questions10,11. Bisoprolol was the first 
beta-blocker to show beneficial effects on outcomes in patients with HF and left ventricular 
systolic dysfunction taking part  in the second Cardiac Insufficiency Bisoprolol Study 
(CIBIS-II)12. A report from the CIBIS-II13 failed to answer thoroughly whether the treatment 
effect in heart failure of this selective β1 antagonist with dual renal and hepatic routes of 
excretion varies by renal function. In our study we sought to expand and extend that analysis 
adjusting for potential confounders and  taking in consideration the non linear relationship 
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between renal function and outcomes in the assessment of treatment by renal function 
interaction. 
Methods 
Source population 
The design, baseline characteristics of the participants in and the principal findings of CIBIS-
II have been published elsewhere12,14.  In brief, CIBIS-II was a double-blind, randomized 
comparison of bisoprolol and placebo in 2647 ambulatory patients with New York Heart 
Association (NYHA) class III and IV HF and a left-ventricular ejection fraction of 35% or 
less. Patients were treated with a diuretic and an ACE-inhibitor (other vasodilators were 
allowed in the case of ACE-inhibitor intolerance) for at least two weeks before 
randomization. Eligible patients were commenced on bisoprolol 1.25 mg or placebo once 
daily, and the dose increased progressively to 2.5 mg, 3.75 mg, 5.0 mg, 7.5 mg and 10.0 mg 
according to tolerance. The trial was stopped prematurely, after a mean follow-up of 1.3 
years, as β-blocker treatment led to a highly significant reduction in the primary endpoint of 
all-cause mortality, with a bisoprolol:placebo hazard ratio  (and 95% confidence intervals) of 
0.66 (0.54, 0.81), p<0.0001.  
 
Baseline renal function 
Renal function impairment, quantified as a serum creatinine (SCr) ≥ 300 μmol/L (3.4 mg/dL) 
at baseline, was an exclusion criterion from CIBIS-II. Because SCr alone is inaccurate in the 
assessment of renal function15, we estimated glomerular filtration rate (eGFR) using the 
Cockcroft-Gault formula16 (recommended for estimation of GFR, together with the 
Modification of Diet in Renal Disease [MDRD] formula17, by the Kidney Disease Outcome 
Quality Initiative guidelines18). Furthermore, to improve eGFR accuracy, we used 
normalization to body surface area19,20 (BSA) that was calculated according to the Du Bois 
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height-weight formula21. In summary: eGFRcg = [(140 – age in years) x (body weight in kg)] 
/ (SCr in μmol/L) x (0.85 if female), BSA = 0.007184 x body weight (in kg)0.425 x height (in 
cm)0.725, eGFRBSA  (eGFRcg corrected for BSA) = eGFRcg x (1.73/BSA) = ml/min per 1.73 
m2. 
 
In keeping with prior studies of the effect of captopril3 and valsartan22 according to renal 
function, in patients with left ventricular dysfunction, heart failure or both after myocardial 
infarction (MI), we divided patients into four eGFRBSA categories: < 45, 45 to <60, 60 to < 
75 and ≥ 75 ml/min per 1.73 m2.  
 
Outcomes evaluated 
In addition to the original study primary endpoint of all-cause mortality, we examined the 
effect of bisoprolol on the post hoc composite outcome of all-cause mortality or heart failure 
hospitalization, a commonly used endpoint in HF trials.  We also evaluated the effect of 
bisoprolol on heart failure hospitalization alone. To evaluate tolerability and safety, we 
evaluated permanent premature treatment withdrawals (a secondary endpoint in the original 
study) and the post hoc composite outcome of all-cause mortality or all-cause hospitalization.  
All medical events, including treatment withdrawals, were blindly reviewed and classified by 
members of an independent Critical Event Committee according to standardized definitions. 
 
Statistical Analysis 
Continuous variables are expressed as medians (with interquartile ranges) and categorical 
variables as counts and percentages. To assess differences in baseline characteristics among 
eGFRBSA categories we used the Kruskal-Wallis test for continuous variables and the χ2 test 
for categorical variables. Kaplan-Meier analyses, stratified according to the eGFRBSA, for 
death from any cause and for all the other end points were determined and presented as event 
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curves, compared by means of log-rank test. Cox proportional hazard models were used to 
compare each clinical outcome according to treatment intervention across eGFRBSA groups. 
Multivariable analysis adjusted for age (years), sex, presence of diabetes mellitus, HF 
etiology (ischemic, idiopathic, others), baseline systolic blood pressure and ejection fraction. 
The proportional hazards assumption was checked using scaled Schoenfeld residuals. To 
ascertain potential heterogeneity of the effect of bisoprolol across the entire spectrum of renal 
function, evidence of treatment by eGFRBSA categories interaction was investigated. 
Analyses were conducted modeling eGFRBSA as a categorical and linear continuous variable. 
To explore the nonlinear relationship between renal function and event free survival, we also 
modeled eGFRBSA as a restricted cubic spline. 
 
All p values were 2 sided, and p < 0.05 was used to determine statistical significance. 
Analyses were all based on intention-to-treat and were performed with STATA, version 10.1 
(StataCorp LP, College Station, TX, USA). 
 
Results 
Baseline characteristics 
A baseline eGFRBSA could be calculated for 2622 participants (99.1% of CIBIS-II patients). 
The 25 subjects without a baseline eGFRBSA did not differ significantly in terms of 
demographic/clinical characteristics, treatment received and major outcomes from the 
population analyzed (data not shown). 
The median eGFRBSA was 64.5 ml/min per 1.73 m2 (IQR 49.9, 81.5). 863 (32.9%) patients 
had an eGFRBSA of at least 75 ml/min per 1.73 m2, 640 (24.4%) had an eGFRBSA of 60 to 
74.9 ml/min per 1.73 m2, 669 (25.5%) had an eGFRBSA of 45 to 59.9 ml/min per 1.73 m2 and 
450 (17.2%) had an eGFRBSA below 45 ml/min per 1.73 m2. The difference between the 
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lowest and highest eGFRBSA category was 52 ml per minute per 1.73 m2 and the difference in 
creatinine was 49 μmol/L (0.6 mg/dL). 
 
Baseline demographic and clinical characteristics for patients in the four eGFRBSA categories 
are shown in Table 1. Lower eGFRBSA was associated with older age, female sex, higher 
frequency of co-morbidities (hypertension, diabetes, coronary artery disease, peripheral and 
cerebrovascular disease) and ischemic etiology. There was no significant difference in the 
severity of HF (expressed as NYHA class), and, although statistically significant, the 
difference in ejection fraction (2%) between eGFRBSA groups was small. There was no 
difference in the allocation of randomized treatment across eGFR categories. 
Among each eGFRBSA group no difference was found in the concomitant treatment with 
diuretic, ACE inhibitors, digoxin and antiplatelet agents whereas patients with lower 
eGFRBSA more often received amiodarone and anticoagulants.  
 
Outcomes 
All cause mortality 
Death occurred in 379 patients during follow up. Figure 1 shows all-cause mortality for each 
eGFRBSA category. Reduced eGFRBSA at baseline was associated with higher mortality. 
Patients in the lowest eGFRBSA category (<45 ml/min per 1.73 m2) had a 2.4 fold higher 
adjusted risk compared with subjects with an eGFRBSA ≥ 75 ml/min per 1.73 m2. Patients in 
the other categories had an intermediate risk:  1.4-fold higher in those with an eGFRBSA 
between 45 and 59.9 ml/min per 1.73 m2  and 1.2-fold higher in those with an eGFRBSA 
between 60 and 74.9 ml/min per 1.73 m2. The adjusted bisoprolol:placebo hazard ratio for 
each eGFRBSA category is shown in table 2. The effect of bisoprolol on all-cause mortality 
was not modified by baseline eGFRBSA category (p for eGFRBSA: treatment interaction = 
0.81).  
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Treating eGFRBSA as a linear continuous variable there was a 13% adjusted risk accrual for 
each 10-unit decrease in baseline renal function (p for eGFRBSA: treatment interaction = 
0.85). The non-significant interaction between eGFRBSA transformed as a restricted cubic 
spline and treatment with bisoprolol and its effect on all-cause mortality is represented 
graphically in figure 2a. 
 
All cause mortality or heart failure hospitalization 
The risk of the composite outcome of all-cause mortality or heart failure hospitalization was 
also associated with renal impairment (figure 3). When compared with patients with normal 
or near normal renal function (≥ 75 ml/min per 1.73 m2) patients with eGFRBSA < 45, 
between 45 and 59.9, between 60 and 74.9 ml/min per 1.73 m2 had  2.5, 1.5 and 1.3 fold 
higher adjusted risks respectively. After multivariable adjustment, the effect of bisoprolol on 
the composite outcome was consistent across renal function groups (table 2) and was not 
influenced by baseline renal function (p for interaction = 0.66).  
Modeling eGFRBSA as a linear continuous variable the adjusted risk accrual for each 10-unit 
decrease in renal function was 14% (p for interaction = 0.62). The graphical representation of 
interaction between bisoprolol and eGFRBSA transformed as a restricted cubic spline, for the 
composite endpoint is presented in figure 2b.  
 
Heart failure hospitalization 
Overall, 386 (14.7%) patients were hospitalized for worsening symptoms of heart failure 
during follow up. Patients in the lowest eGFRBSA category had a 2.9 fold higher adjusted risk 
of being hospitalized for worsening heart failure compared with subjects with eGFRBSA ≥ 75 
ml/min per 1.73 m2 whereas the risk of hospital admission was 1.8 fold and 1.3 fold higher 
for patients with an eGFRBSA of 45 to 59.9 and 60 to 74.9 ml/min per 1.73 m2 respectively. 
The adjusted bisoprolol:placebo hazard ratios for each eGFRBSA category are shown in table 
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2. The hazard ratio appeared to fall further as eGFRBSA increased into the near normal range, 
an impression reinforced by the graphical representation of interaction between bisoprolol 
and eGFRBSA transformed as a restricted cubic spline (figure 2c). However, the test for 
interaction was not statistically significant whether eGFRBSA was tested as a categorical 
(p=0.71) or a continuous (p=0.47) variable. 
 
Tolerability and safety 
During the entire duration of follow up the average daily dose of both bisoprolol and placebo 
was significantly lower for patients with baseline renal impairment (table 1). Moreover the 
dose of bisoprolol was significantly lower than the dose of placebo across all the eGFRBSA 
categories. Nonetheless, after 3 months of follow up there was a trend towards a greater 
reduction in heart rate in patients in the lowest eGFRBSA category amongst those allocated to 
bisoprolol, compared with placebo (p for treatment-eGFRBSA interaction = 0.14) [table 3].  
Similarly, there was trend for more of a reduction of diastolic blood pressure with bisoprolol, 
compared with placebo, in the lowest eGFRBSA category (p for treatment:eGFRBSA 
interaction = 0.18). The greatest fall in systolic blood pressure between baseline and 3 
months was in patients with the worst baseline renal function but there was no between-
treatment difference in this change (treatment-eGFRBSA interaction p value = 0.40).  
In patients with a baseline eGFRBSA < 45 ml/min per 1.73 m2 there was a substantially higher 
rate of permanent discontinuation of bisoprolol than placebo (HR 1.54, CI 95% 1.01 to 2.33), 
as shown in figure 4 and table 2. Conversely, in those with baseline eGFRBSA ≥ 75 ml/min 
per 1.73 m2, the risk of drug discontinuation was lower for patients allocated to bisoprolol 
than among those allocated to placebo (HR 0.54, CI 95% 0.35 to 0.85). The relationship 
between baseline eGFRBSA on the risk of drug discontinuation (transformed as a restricted 
cubic spline) is illustrated further in figure 2d.  
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The effect of bisoprolol on the  outcome of our post hoc global safety outcome of all-cause 
mortality or all-cause hospitalization was consistent across each eGFRBSA category (table 2) 
and unmodified by baseline renal function (p for interaction = 0.81). No significant 
interaction was observed when eGFRBSA was modeled as a linear continuous variable (p for 
interaction = 0.77).  
 
Discussion 
The main finding from the present analysis of CIBIS-II was the consistency of clinical 
benefit derived from bisoprolol across the entire spectrum of renal function as quantified 
using the body surface area adjusted Cockcroft and Gault formula. The role of renal 
insufficiency as a predictor of negative outcomes in patients with HF was also confirmed. As 
a consequence, the absolute benefit attributable to bisoprolol was higher for the primary and 
post hoc composite outcomes in patients with a reduced compared to a normal or near normal 
eGFRBSA. This benefit was realized despite patients with worse renal function achieving a 
lower dose of and having a higher rate of discontinuation of bisoprolol. 
 
Renal function in heart failure 
While renal insufficiency is a common and challenging co-morbidity in patients with HF in 
every day clinical practice6,7, such patients have been underrepresented in clinical trials, most 
of which excluded patients with a serum creatinine >2.0-2.5mg/dL23,24,25,26. Consequently, 
the efficacy and tolerability of treatments in this large and high risk subgroup of patients has 
not been well documented. Understanding the tolerability and efficacy of beta-blockers in 
such patients is very relevant. Although over-activation of the sympathetic nervous system is 
thought to contribute to disease progression and poor outcomes in both HF27 and chronic 
kidney disease28 (CKD), acute administration of a beta-blocker can result in initial 
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depression of ventricular function29 and may also reduce renal blood flow, potentially 
leading to worsening of kidney function30. However in the longer term, beta-blockers 
improve ventricular function and clinical outcomes in patients with HF12,31,32,33,34,35. 
CIBIS-II had a less stringent renal exclusion criterion than many trials, allowing enrolment of 
patients with a creatinine of up to 3.4 mg/dL (300 μmol/L). As a result, more than 40% of 
patients in CIBIS-II had moderate to severe renal dysfunction, namely an eGFRBSA < 60 
ml/min per 1.73 m2 according to the National Kidney Foundation Kidney Disease Outcomes 
Quality Initiative18.  
  
Effects of bisoprolol according to renal function 
Our analysis has shown that in stable patients with moderate to severe heart failure caused by 
reduced left ventricular systolic function, addition of the selective β1 antagonist bisoprolol 
which has a dual route of excretion to standard treatment with a diuretic and an ACE 
inhibitor reduced all-cause mortality, regardless of baseline renal function. Although there 
was some suggestion that the effect of bisoprolol to reduce the risk of heart failure 
hospitalization was greater in patients with a near normal eGFRBSA the test for interaction 
was not statistically significant.  
Only two other studies have examined the effects of beta blockade in the setting of HF and 
concomitant renal insufficiency. A post hoc analysis from the Metoprolol CR/XL 
Randomized Intervention Trial in Chronic HF (MERIT-HF) focused on the efficacy of 
metoprolol, a beta-1 selective blocker with a predominantly hepatic route of excretion, 
according to different baseline renal function. Interestingly and in contrast to what we found 
with bisoprolol, the relative risk reduction with metoprolol was greater in patients in the 
lowest compared to highest eGFR category10. Why this should be is not clear but may be due 
to differences between the studies. The proportion of patients in the lowest eGFR category 
was higher in CIBIS-II than MERIT-HF (17.2% versus 12.4% of patients, respectively). For 
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patients allocated to placebo the mortality rate was also higher in the lowest eGFR category 
in CIBIS-II compared to MERIT-HF: in CIBIS-II 61/235 (26.0%) of patients with an eGFR 
<45 ml/min per 1.73 m2 died compared to 44/224 (19.6%) of these patients in MERIT-HF. 
Another post hoc analysis from the SENIORS trial (Study of the Effects of Nebivolol 
Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure) recently 
suggested that the efficacy of nebivolol was not reduced in elderly HF patients with mild or 
moderate renal impairment. Similar to our findings, a non significant interaction between 
baseline renal function and the effect of nebivolol was found11. Like metoprolol, metabolism 
and elimination of nebivolol is almost entirely hepatic with a minimal amount of the drug 
excreted unchanged in the urine. Nevertheless, some important differences between 
SENIORS and CIBIS-II design must be considered. In SENIORS patients were excluded if 
their baseline serum creatinine was higher than 2.8 mg/dL (250 μmol/L). Moreover, the 
enrollment of patients with mildly symptomatic HF (more than 50% were in NYHA class I-
II) and with an ejection fraction >35% (more than one third of the entire population) was 
permitted. 
 
We found a trend towards a greater reduction in heart rate and diastolic blood pressure with 
bisoprolol (compared to placebo) in patients with the most reduced renal function. This might 
be explained by greater sympathetic over-activity in patients with the worst renal function 
(although baseline heart rate did not vary notably across eGFRBSA categories, similar to what 
was reported in MERIT-HF) or could be due to bisoprolol accumulation in those patients. In 
keeping with this latter hypothesis was the higher rate of permanent treatment withdrawals 
observed in the lowest eGFRBSA category amongst patients allocated to bisoprolol. Of note, 
the rate of discontinuation of metoprolol (compared to placebo), for adverse events, was not 
increased in the lowest eGFR category in MERIT-HF, although overall discontinuation rates 
were not reported. It is possible that accumulation of bisoprolol could have led to a decline in 
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renal function and sodium and water retention. Although this has been demonstrated to occur 
acutely in response to a single large intravenous dose of bisoprolol in patients with 
hypertension30, we do not know if this occurs chronically in patients with heart failure and 
serial measurement of renal function was not performed in CIBIS-II.  It needs to be re-
iterated, however, that a larger absolute benefit was obtained with bisoprolol in patients in 
the lowest (compared to the highest) eGFRBSA category in CIBIS-II.  
 
The only other relevant study we know of is a small placebo-controlled trial in which the 
effects of carvedilol on mortality and morbidity were investigated in 114 patients with end-
stage renal disease and associated dilated cardiomyopathy receiving regular hemodialysis.  
After one year of carvedilol therapy left ventricular function improved compared to placebo. 
At two years follow up, the number of deaths in the carvedilol group was 30 (51.7%) 
compared to 41 (73.2%) in the placebo group (p < 0.01). Moreover, significantly fewer 
patients receiving carvedilol were admitted to hospital36.Unfortunately, because of the design 
of this study we cannot compare dose of treatment achieved, hemodynamic effects and 
discontinuation rates according to the degree of renal dysfunction at baseline. 
 
Our study has a number of strengths. To the best of our knowledge no previous report has 
investigated the interaction between renal dysfunction and the effect of bisoprolol on 
mortality and heart failure hospitalization in patients with HF in advanced NYHA class. 
Moreover, we also investigated the tolerability and safety of bisoprolol in this clinical setting. 
In CIBIS-II, given the high serum creatinine threshold allowed for enrolment, almost half of 
the entire population presented moderate to severe renal impairment. A number of limitations 
should also be noted. Renal function was estimated and not measured by means of reference 
method (e.g. iothalamate clearance). We used the Cockcroft-Gault formula to estimate 
glomerular filtration rate as done in several previous studies1,2,37. Furthermore, we 
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normalized for body surface area to increase the accuracy of the original equation19,38. We 
found that 43% of patients had an eGFR < 60 ml/min whilst in a previous analysis of CIBIS-
2 this proportion was 32%13. This discrepancy is due to the different equations used and we 
believe that our analysis better represents the true renal function in this cohort. Measurement 
of renal function was made on only one occasion in the present study, thus limiting our 
ability to examine the impact of bisoprolol on renal function during follow up. Other 
potential prognostic confounders such as hemoglobin were not measured. Nevertheless, their 
association with impaired estimated renal function makes it unlikely that important 
distortions of the effect of bisoprolol have occurred.  
 
Clinical implications 
Among patients with HF due to left ventricular systolic dysfunction bisoprolol was effective, 
regardless baseline renal impairment. Therefore, the value of beta-blockers should be 
reinforced amongst those with HF and CKD, especially as the absolute gains may be higher. 
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Figure Legends 
 
Figure 1. Title: Kaplan-Meier survival function for all-cause mortality according to renal 
function. Caption: plotted lines:  Bisoprolol (────),   Placebo (────); A) eGFRBSA < 45 
ml/min per 1.73 m2,   B) eGFRBSA 45 to < 60 ml/min per 1.73 m2, C) eGFRBSA 60 to < 75 
ml/min per 1.73 m2,   D) eGFRBSA ≥ 75 ml/min per 1.73 m2. Legend: eGFRBSA = estimated 
glomerular filtration rate corrected for body surface area 
 
Figure 2. Title: Unadjusted effect of treatment according to eGFRBSA modeled as a restricted 
cubic spline. Caption: Bisoprolol effect (–––––), 95% confidence interval (− − − −), hazard 
ratio 1 (– · – · –). Legend: eGFRBSA = estimated glomerular filtration rate corrected for 
body surface area, HR = hazard ratio, WHFH = worsening heart failure hospitalization 
 
Figure 3. Title: Kaplan-Meier survival function for all-cause mortality or hospital 
admissions for worsening heart failure according to renal function. Caption: plotted lines:  
Bisoprolol (────),   Placebo (────); A) eGFRBSA < 45 ml/min per 1.73 m2,   B) 
eGFRBSA 45 to < 60 ml/min per 1.73 m2, C) eGFRBSA 60 to < 75 ml/min per 1.73 m2,   D) 
eGFRBSA ≥ 75 ml/min per 1.73 m2 Legend: eGFRBSA = estimated glomerular filtration rate 
corrected for body surface area, WHFH = worsening heart failure hospitalization 
 
Figure 4. Title: Kaplan-Meier survival function for permanent treatment withdrawals 
according to renal function. Caption: plotted lines:  Bisoprolol (────),   Placebo (────); 
A) eGFRBSA < 45 ml/min per 1.73 m2,   B) eGFRBSA 45 to < 60 ml/min per 1.73 m2, C) 
eGFRBSA 60 to < 75 ml/min per 1.73 m2,   D) eGFRBSA ≥ 75 ml/min per 1.73 m2 
Legend: eGFRBSA = estimated glomerular filtration rate corrected for body surface area 
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Table 1. Baseline characteristics according to eGFRBSA 
 
Variable  
eGFRBSA < 45.0 
ml/min per 1.73 m2 
N=450 
eGFRBSA 45.0 – 59.9 
ml/min per 1.73 m2 
N=669 
eGFRBSA 60.0 – 74.9 
ml/min per 1.73 m2 
N=640 
eGFRBSA ≥75.0 
ml/min per 1.73 m2 
N=863 
 
p value 
Randomized treatment Placebo 235 (52.2%) 308 (46.0%) 320 (50.0%) 447 (51.8%) 
0.10 
 Bisoprolol 215 (47.8%) 361 (54.0%) 320 (50.0%) 416 (48.2%) 
Median age (IQR), years  71 (66,  75) 67 (61,  72) 61 (56,  67) 53 (46,  59) < 0.001 
Sex Female 204 (45.3%) 177 (26.5%) 79 (12.3%) 50 (5.8%) 
< 0.001 
 Male 246 (54.7%) 492 (73.5%) 561 (87.7%) 813 (94.2%) 
Median BMI* (IQR)  24.8 (22.6,  27.3) 25.7 (23.7,  28.1) 26.4 (24.3,  29.0) 28.0 (25.5,  30.7) < 0.001 
Smoking history Never 218 (48.4%) 285 (42.8%) 214 (33.4%) 271 (31.4%) 
< 0.001  Former 189 (42.0%) 300 (45.0%) 310 (48.4%) 393 (45.5%) 
 Current 43 (9.6%) 81 (12.2%) 116 (18.2%) 199 (23.1%) 
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Medical history 
Hypertension 
 
 
225 (50.0%) 
 
303 (45.3%) 
 
268 (41.9%) 
 
346 (40.1%) 
 
0.004 
Diabetes mellitus  74 (16.4%) 88 (13.2%) 61 (9.5%) 85 (9.8%) 0.001 
Coronary artery disease  328 (72.9%) 452 (67.6%) 426 (66.6%) 496 (57.5%) < 0.001 
Valve disease  77 (17.1%) 84 (12.6%) 64 (10.0%) 54 (6.3%) < 0.001 
Cerebrovascular disease  43 (9.6%) 55 (8.2%) 56 (8.8%) 43 (5.0%) 0.006 
Peripheral arterial disease  45 (10.0%) 71 (10.6%) 41 (6.4%) 36 (4.2%) < 0.001 
Percutaneous  coronary intervention  19 (4.2%) 32 (4.8%) 25 (3.9%) 40 (4.6%) 0.86 
Cardiac surgery  88 (19.6%) 109 (16.3%) 96 (15.0%) 80 (9.3%) < 0.001 
Heart Failure Etiology Ischemic 248 (55.1%) 346 (51.7%) 325 (50.8%) 386 (44.7%) 
0.03  PDCM 28 (6.2%) 69 (10.3%) 77 (12.0%) 140 (16.2%) 
 Others** 174 (38.7%) 254 (38.0%) 238 (37.2%) 337 (39.1%) 
NYHA¶ Class III 370 (82.2%) 558 (83.4%) 531 (83.0%) 719 (83.3%) 0.95 
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 IV 80 (17.8%) 111 (16.6%) 109 (17.0%) 144 (16.7%) 
Median HR║ (IQR), beats/min  78 (70,  88) 77 (69,  88) 78 (68,  89) 80 (70,  91) 0.08 
Atrial Fibrillation  90 (20.0%) 129 (19.3%) 133 (20.8%) 166 (19.2%) 0.87 
Median SBP# (IQR), mmHg  126 (112,  140) 130 (115,  140) 128 (115,  140) 130 (120,  140) 0.77 
Median DBP† (IQR), mmHg  80 (70,  80) 80 (70,  86) 80 (70,  90) 80 (70,  90) < 0.001 
Median creatinine (IQR), μmol/L  133 (111, 159) 113 (97.2, 124) 99 (89, 108.7) 84 (75, 94) < 0.001 
Median eGFRBSA§ (IQR) ml/min/1.73 m2  38.4 (32.9,  42.1) 52.4 (48.9,  56.2) 67.0 (63.6,  71.0) 90.4 (81.6,  102.3) < 0.001 
Median left ventricular EF‡ (IQR), %  28 (22.7,  32) 28 (23,  32) 28.9 (24.1,  32.1) 29.6 (24.1,  33) < 0.001 
Average daily dose (mg) 
Placebo 6.8 (2.8) 7.1 (2.7) 7.4 (2.6) 7.6 (2.5) 0.007 
Bisoprolol 5.6 (3.2) 6.0 (3.1) 6.1 (3.0) 6.8 (2.8) < 0.001 
Median daily dose (mg) 
Placebo 8.3 (4.7, 9.2) 8.8 (4.9, 9.3) 8.9 (5.5, 9.3) 9.0 (6.7, 9.3) 0.007 
Bisoprolol 6.1 (2.4, 9.0) 7.0 (2.8, 9.1) 6.6 (3.4, 9.2) 7.7 (4.2, 9.2) < 0.001 
Co-medication       
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Diuretic 
Spironolactone 
ACE Inhibitor 
Digoxin 
Amiodarone 
Anticoagulants 
Antiplatelet agents 
448 (99.6%) 
47 (10.4%) 
423 (94.0%) 
227 (50.4%) 
90 (20.0%) 
154 (34.2%) 
173 (38.4%) 
661 (98.8%) 
72 (10.8%) 
634 (94.8%) 
353 (52.8%) 
103 (15.4%) 
204 (30.5%) 
286 (42.8%) 
634 (99.1%) 
63 (9.8%) 
602 (94.1%) 
320 (50.0%) 
102 (15.9%) 
182 (28.4%) 
271 (42.3%) 
858 (99.4%) 
88 (10.2%) 
827 (95.8%) 
451 (52.3%) 
93 (10.8%) 
220 (25.5%) 
344 (40.0%) 
0.44 
0.32 
0.37 
0.70 
< 0.001 
0.008 
0.06 
 
* BMI = body mass index, † DBP = diastolic blood pressure, ‡ EF = ejection fraction, § eGFRBSA= estimated glomerular filtration rate corrected for 
body surface area, ║HR = heart rate, ¶ NYHA = New York Heart Association, # = systolic blood pressure 
To convert creatinine values to mg/dl, divide by 88.4. 
** Others : patients with valvular disease or hypertension, together with those with suspected but unproved ischaemic heart disease or 
cardiomyopathy 
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Table 2. Proportional hazards ratios for all the outcomes under study across eGFRBSA categories 
 
 
Outcome 
 Creatinine Clearance Category (ml/min per 1.73 m2)  
 
Test for 
interaction ‡ 
< 45 
N=450 
45 to < 60 
N=669 
60 to < 75 
N=640 
≥ 75 
N=863 
All-cause mortality 
No of events (%) 105 (23.3%) 98 (14.6%) 87 (13.6%) 89 (10.3%) 
0.81 (0.85) Bisoprolol /Placebo 
HR* (95% CI†) 
0.71 (0.48 – 1.05) 0.69 (0.46 – 1.04) 0.53 (0.34 – 0.82) 0.64 (0.42 – 0.99) 
All-cause mortality or hospital 
admissions for worsening heart failure 
No of events (%) 165 (36.7%) 169 (25.3%) 148 (23.1%) 156 (18.1%) 
0.66 (0.62) Bisoprolol /Placebo 
HR (95% CI) 
0.72 (0.53 to 0.99) 0.66 (0.49 to 0.91) 0.55 (0.39 to 0.77) 0.56 (0.40 to 0.78) 
Heart failure hospitalization 
No of events (%) 99 (22.0%) 112 (16.7%) 82 (12.8%) 93 (10.8%) 
0.71 (0.47) Bisoprolol /Placebo 
HR (95% CI) 
0.76 (0.51 to 1.14) 0.66 (0.45 to 0.97) 0.54 (0.34 to 0.85) 0.52 (0.34 to 0.80) 
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All-cause mortality or all-cause 
hospital admission 
No of events (%) 261 (58.0%) 286 (42.7%) 256 (40.0%) 286 (33.1%) 
0.81 (0.77) Bisoprolol /Placebo 
HR (95% CI) 
0.82 (0.64 to 1.05) 0.72 (0.57 to 0.92) 0.69 (0.54 to 0.89) 0.77 (0.61 to 0.98) 
Permanent treatment withdrawals 
No of events (%) 95 (21.1%) 114 (17.0%) 81 (12.7%) 89 (10.3%) 
0.01 
(<0.001) Bisoprolol /Placebo 
HR (95% CI) 
1.54 (1.01 to 2.33) 1.05 (0.71 to 1.55) 0.76 (0.48 to 1.19) 0.54 (0.35 to 0.85) 
* HR = hazard ratio, † CI = confidence interval 
‡ For interaction test, value in brackets is for test using continuous rather than categorical variable. 
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Table 3.  Median (interquartile range) change in heart rate, systolic blood pressure (BP) and diastolic BP between baseline and 3 months of follow-
up. 
Change from baseline to 
3 months follow-up 
Randomized 
Treatment 
eGFRBSA* < 45.0 
ml/min per 1.73 m2 
eGFRBSA 45.0 – 59.9 
ml/min per 1.73 m2 
eGFRBSA 60.0 – 74.9 
ml/min per 1.73 m2 
eGFRBSA ≥75.0 
ml/min per 1.73 m2 
p value 
Interaction 
p value 
Heart rate 
Placebo 0 (-7, 10) 2 (-5, 10) -0.5 (-8, 8) -2 (-6, 10) 0.5 
0.14 
Bisoprolol -15 (2, 25.5) -12 (2, 22) -11 (2, 20) -10 (1, 20) 0.04 
Systolic BP † 
Placebo -10 (-10, 30) -5 (-5, 21) -4 (-10, 20) -4 (-10, 20) 0.04 
0.40 
Bisoprolol -10 (-5, 50) -5 (-10, 20) -5 (-5, 20) -2 (-8, 20) 0.02 
Diastolic BP 
Placebo 0 (-6, 8) 0 (-5, 10) 0 (-5, 10) 0 (-5, 10) 0.36 
0.18 
Bisoprolol -3 (-2, 10) 0 (-5, 10) 0 (-5, 10) 0.5 (-5, 10) 0.38 
* eGFRBSA = estimated glomerular filtration rate corrected for body surface area, † BP = blood pressure 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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